Higashi T, Kawamata F, Dogen M
J Biochem. 1976 Aug;80(2):259-65. doi: 10.1093/oxfordjournals.jbchem.a131272.
Kidney catalase [EC 1.11.1.6] was doubly labeled by injecting a mixture of [14C]-leucine and delta-amino[3H]levulinic acid (ALA) into normal and allyliso-(2-isopropyl-4-pentenoyl)urea (Sedormid)-treated rats. Shortly after the injection of a tracer dose or the precursors, catalase in microsomes showed the highest specific radioactivities among catalases from various cell fractions. On the other hand, peroxisomal catalase was labeled gradually, reaching a plateau at about 90 min. The patterns of incorporation of both isotopes were similar to those obtained previously with rat live catalase, except that the 3H-radioactivities were much higher. From the results obtained it could be postulated that kidney catalase is synthesized on polysomes and then transferred to peroxisomes, directly or via the soluble phase. The ratio of 3H/14C incorporated was lowest in microsomal catalase, highest in microsomal catalase, highest in peroxisomal enzyme and intermediate in catalase of the soluble fraction. The increment with time was large in the latter two catalases, while the former showed a rather small change. The evidence suggests that nascent catalase contains less heme than the completed molecule; further addition of heme to this intermediate seems to occur in the cytosol, and possibly also in peroxisomes. Administration of a porphyrinogenic drug, (2-isopropyl-4-pentenoyl)urea, produced a remarkable decrease in the incorporation of [3H]ALA into kidney catalase, with no significant effect on that of [14C]leucine.
通过向正常大鼠和经烯丙基异-(2-异丙基-4-戊烯酰)脲(速可眠)处理的大鼠注射[14C]-亮氨酸和δ-氨基[3H]乙酰丙酸(ALA)的混合物,对肾脏过氧化氢酶[EC 1.11.1.6]进行双重标记。在注射示踪剂量或前体后不久,微粒体中的过氧化氢酶在来自各种细胞组分的过氧化氢酶中显示出最高的比放射性。另一方面,过氧化物酶体过氧化氢酶被逐渐标记,在约90分钟时达到平稳期。两种同位素的掺入模式与先前用大鼠肝脏过氧化氢酶获得的模式相似,只是3H放射性要高得多。从获得的结果可以推测,肾脏过氧化氢酶在多核糖体上合成,然后直接或通过可溶性相转移到过氧化物酶体。微粒体过氧化氢酶中3H/14C掺入比最低,过氧化物酶体酶中最高,可溶性组分的过氧化氢酶中居中。后两种过氧化氢酶随时间的增加幅度较大,而前者变化较小。证据表明,新生的过氧化氢酶含有的血红素比完整分子少;血红素似乎在细胞质中,也可能在过氧化物酶体中进一步添加到这个中间体上。给予一种致卟啉药物(2-异丙基-4-戊烯酰)脲,导致[3H]ALA掺入肾脏过氧化氢酶的量显著减少,而对[14C]亮氨酸的掺入没有显著影响。